10x Genomics revenue and financials

TXG · NASDAQ · USD

$80.66−17.47%−$17.08

Close · October 6, 2026

In the fiscal year ended December 2025, 10x Genomics reported revenue of $642.82M (+5.25% year over year). The net loss was $43.54M.

Annual revenue · 2025: $642.82M

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total assets	1,030	1,016	1,041	1,027	980	903	919	938	930	923	965	949
Current assets	675	670	684	660	656	580	584	594	579	567	596	562
Cash and equivalents	503	490	474	433	398	377	344	398	380	356	359	311
Short-term investments	49.5	49.6	49.4	49.6	49.5	49.8	49.3	—	0.3	16.0	29.4	45.6
Receivables	50.6	56.1	82.5	96.6	119	52.5	88.5	83.5	91.2	91.3	115	104
Inventory	52.6	53.5	56.3	62.0	69.0	74.7	83.1	94.1	88.3	83.2	73.7	80.9
Net property, plant and equipment	272	279	287	296	302	302	310	318	324	332	345	354
Goodwill	6.9	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5
Other intangible assets	61.2	59.9	62.3	64.8	14.7	15.2	15.7	16.1	16.7	16.1	16.6	21.8
Current liabilities	119	114	153	147	112	108	118	121	111	109	127	105
Accounts payable	20.7	17.4	12.7	18.1	15.9	10.1	12.9	26.2	21.2	20.2	15.7	18.8
Total debt	78.8	81.4	84.4	87.0	86.7	—	—	—	—	—	—	—
Total liabilities	205	201	245	242	207	196	209	215	206	204	224	203
Total equity (incl. minority)	826	814	796	785	773	707	710	723	724	719	741	745
Retained earnings	-1,542	-1,524	-1,511	-1,494	-1,467	-1,501	-1,467	-1,418	-1,382	-1,344	-1,284	-1,235